The performance capability of your laboratory’s LIS goes way beyond its ability to participate in these new value-based care initiatives—the right LIS is critical to your practice to ensure success and increased revenue.

The Dark Report is pleased to offer this FREE White Paper, providing an enlightening overview of pharmacogenomic testing and how PGx fits into current healthcare goals, a discussion of the obstacles healthcare providers, institutions and clinical diagnostic laboratories face in entering the pharmacogenomic testing market, and examples of how a cloud-based, Software-as-a-Service platform can help healthcare providers overcome those obstacles.

With less revenue flowing from reimbursements and more consumers footing the bill for diagnostic testing, counterbalancing lost revenue while better serving providers and patients is not an option—it is a must. The Dark Report is pleased to offer this FREE White Paper, exploring three critical rules innovative medical laboratories must take into account to combat new and drastic changes occurring in the lab industry, and outlining proactive steps that when taken, will serve as the foundation for clinical success in 2017 and beyond.

Increasing understanding of the genetic basis of an individual’s response to drugs, including how and how quickly a drug is metabolized (pharmacodynamics and pharmacokinetics), has opened the door to an increasingly personalized approach to drug prescription. By identifying drugs most likely to benefit a patient, assessing the likely dose response, potentially avoiding adverse reactions, and reducing unnecessary use of drugs,  pharmacogenomics testing (PgX) is helping to optimize treatment and reduce costs associated with complications or inappropriate utilization.

As molecular technology and personalized medicine increasingly becomes the default position for clinical diagnostics laboratories, these modalities place significant demands on laboratory information systems. Although hospitals and healthcare institutions often focus on an enterprise-wide electronic medical records system that includes a laboratory information system (LIS), those LIS’s do not typically have the functionality needed to handle current molecular testing needs, let alone those expected in the near future.